Ocular Therapeutix

Ocular Therapeutix (NSDQ:OCUL) this week posted third-quarter results that missed the overall consensus on Wall Street.

The Bedford, Massachusetts-based company reported net losses of $24.2 million, or -31¢ per share, on sales of $11.97 million for the three months ended Sept. 30, for a bottom-line loss over Q3 2021 when it reported $2.65 million in profits. Sales were down 1.55% year-over-year.

Earnings per share were 7¢ behind The Street, where analysts were looking for sales of $14.27 million.

“We presented arguably the most important clinical data in the company’s history at this year’s AAO meeting,” President and CEO Antony Mattessich said in a news release. “In the 7-month data from our U.S.-based Phase 1 clinical trial of a 600 µg, single implant OTX-TKI for the treatment of controlled wet AMD, 80% and 73% of subjects were rescue-free up to 6 and 7 months, respectively. In addition to our goal of moving OTX-TKI into a Phase 2/3 trial for the…

Ocular Therapeutix (NSDQ:OCUL) this week posted first-quarter results that beat the earnings consensus on Wall Street but missed revenue estimates.

The Bedford, Massachusetts-based company reported losses of $12.5 million, or -16¢ per share, on sales of $13.2 million for the three months ended March 31, for sales growth of 79.6% compared with Q1 2021.

Earnings per share were 9¢ ahead of The Street, where analysts were looking for sales of $13.96 million.

“We have had a solid start to the year,” Antony Mattessich, president and CEO, said in a news release. “Following a slowdown in cataract surgeries in January due to a spike in COVID-19 infections as a result of the Omicron variant, we saw a rebound in sales as the quarter progressed, culminating in approximately 10,500 billable units sold to ASCs and HOPDs in March—a monthly record by more than 500 units.”

Ocular Therapeutix projects total net product revenue in 2022 to be in the range…

Ocular Therapeutix (NSDQ:OCUL) shares ticked up today despite fourth-quarter results that missed the consensus revenue forecast.

The Bedford, Massachusetts-based company posted losses of $3.9 million, or 5¢ per share, on sales of $12.3 million for the three months ended Dec. 31, 2021, for a massive bottom-line gain moving from $85.6 million in losses this time last year towards breakeven on sales growth of 67.5%.

Adjusted to exclude one-time items, losses per share were 23¢, coming in level with projections on Wall Street, where analysts were looking for sales of $14.4 million.

“Ocular has had another strong quarter and a productive year,” Ocular Therapeutix President and CEO Antony Mattessich said in a news release. “Overall, we made great progress and look forward to a busy 2022 that will further advance our strong position within ophthalmology.”

Ocular Therapeutix did not provide financial guidance for the 2022 fiscal year.

OCUL sh…

Ocular Therapeutix (NSDQ:OCUL) announced today that it reported positive results from a Phase 2 trial of its dry eye disease treatment.

Bedford, Massachusetts-based Ocular Therapeutix’s U.S.-based Phase 2 clinical trial evaluated OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of dry eye disease.

Get the full story at our sister site, Drug Delivery Business News.

Ocular Therapeutix (NSDQ:OCUL) announced today that an appeals court invalidated a drug delivery system patent held by Mati Therapeutics.

The U.S. Court of Appeals for the Federal Circuit in Washington, D.C., invalidated the patent related to a drug delivery system containing dexamethasone, affirming the judgment made in June 2020 by the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office.

Get the full story at our sister site, Drug Delivery Business News.

Ocular Therapeutix (NSDQ:OCUL) announced today that its Phase 2 clinical trial for treating dry eye disease (DED) did not meet its primary endpoint.

Bedford, Massachusetts-based Ocular Therapeutix’s U.S.-based, randomized, double-masked, multi-center, vehicle-controlled Phase 2 clinical trial evaluated OTX-CSI (cyclosporine intracanalicular insert) for treating DED by measuring signs and symptoms of DED in 140 subjects treated in both eyes over approximately 16 weeks.

Get the full story at our sister site, Drug Delivery Business News.

Ocular Therapeutix (NSDQ:OCUL) shares ticked up this morning on second-quarter results that topped revenue forecasts.

OCUL shares were up 7.6% at $11.55 just after the market opened this morning. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — remains unmoved at this early stage.

Get the full story at our sister site, Drug Delivery Business News.

Ocular Therapeutix (NSDQ:OCUL) reported first-quarter results that missed the consensus forecast on Wall Street.

The Bedford, Mass.–based eye disease therapeutic developer posted profits of $3.12 million, or $0.04 per share, on sales of $7.34 million for the three months ended March 31, 2021, for a bottom-line leap of 114% on sales growth of 181% compared with Q1 2020.

Get the full story on our sister site, Drug Delivery Business News.

Ocular Therapeutix (NSDQ:OCUL) shares slid this morning on fourth-quarter results that missed the consensus forecast.

The Bedford, Mass.-based eye disease therapeutic developer posted losses of -$85.6 million, or -$1.21 per share, on sales of $7.3 million for the three months ended Dec. 31, 2020, for a massive bottom-line slide from losses of -$26 million last year despite more than tripling revenue numbers from $2.3 million.

Get the full story at our sister site, Drug Delivery Business News.